THE INFLUENCE OF PREBIOTIC AND PROBIOTIC ON THE SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO)

Marcin Szczepanik; Jakub Senko; Kornelia Tyczka; Joanna Kulpa; Zofia Suchanek

doi:10.31435/ijitss.3(51).2026.6162

Authors

Marcin Szczepanik Independent Public Voivodeship Integrated Hospital in Szczecin, Szczecin, Poland https://orcid.org/0009-0004-0475-6187
Jakub Senko Pomeranian Medical University in Szczecin, Poland https://orcid.org/0009-0006-2878-5737
Kornelia Tyczka Independent Public Voivodeship Integrated Hospital in Szczecin, Szczecin, Poland https://orcid.org/0000-0001-8700-2372
Joanna Kulpa Pomeranian Medical University in Szczecin, Poland https://orcid.org/0009-0007-7057-6282
Zofia Suchanek Independent Public Voivodeship Integrated Hospital in Szczecin, Szczecin, Poland https://orcid.org/0009-0003-6911-230X

DOI:

https://doi.org/10.31435/ijitss.3(51).2026.6162

Keywords:

SIBO, Probiotics, Prebiotics, Saccharomyces, Bifidobacterium, Lactobacillus

Abstract

Background: SIBO is a significant and growing problem in the XXI century. Patients suffer from symptoms that inconvenience their everyday life. Despite numerous trials existing SIBO treatment does not fully alleviate patients’ symptoms. Prebiotics and probiotics have proved and widely recognized benefits for gut health, which could be influential for SIBO treatment and for more severe disorders like cirrhosis.

Aim: This narrative review synthesizes evidence on the influence of prebiotics and probiotics on human health, especially in SIBO.

Material and methods: A search of relevant research databases was conducted to identify eligible papers.

Results: Many studies showed that supplementation of prebiotics and probiotics may alleviate the prevalence and severity of SIBO symptoms. Correlation of those therapeutic agents, especially probiotics with antibiotics like rifaximin may bring additional benefits. However, further multi-center studies are required.

Conclusions: Prebiotics and probiotics may be an important factor in the SIBO therapeutic path.

References

Waśkow, M., Tańska, M., & Glowinski, S. (2026). Hydrogen production dynamics during lactulose breath testing in patients with suspected SIBO. Journal of Clinical Medicine, 15(11).

Li, Y., He, H., Chen, L., Chen, J., Gu, M., Hu, Y., et al. (2026). Small intestinal bacterial overgrowth in metabolic dysfunction-associated steatotic liver disease: Prevalence, subtypes, and risk factors across disease spectrum and comorbidity profiles. Biomedicines, 14(5).

Skrzydło-Radomańska, B., & Cukrowska, B. (2022). How to recognize and treat small intestinal bacterial overgrowth? Journal of Clinical Medicine, 11(20).

Puoti, M. G., Assa, A., Benninga, M. A., Broekaert, I., Dolinsek, J., Homan, M., et al. (2025). Small intestinal bacterial overgrowth in children: An expert review by the ESPGHAN Gastroenterology Committee. Journal of Pediatric Gastroenterology and Nutrition, 81(4), 986–999.

Silva, B. C. D., Ramos, G. P., Barros, L. L., Ramos, A. F. P., Domingues, G., Chinzon, D., et al. (2025). Diagnosis and treatment of small intestinal bacterial overgrowth: An official position paper from the Brazilian Federation of Gastroenterology. Arquivos de Gastroenterologia, 62, e24107.

Bevilacqua, A., Campaniello, D., Speranza, B., Racioppo, A., Sinigaglia, M., & Corbo, M. R. (2024). An update on prebiotics and on their health effects. Foods, 13(3).

Davani-Davari, D., Negahdaripour, M., Karimzadeh, I., Seifan, M., Mohkam, M., Masoumi, S. J., et al. (2019). Prebiotics: Definition, types, sources, mechanisms, and clinical applications. Foods, 8(3).

Smolinska, S., Popescu, F. D., & Zemelka-Wiacek, M. (2025). A review of the influence of prebiotics, probiotics, synbiotics, and postbiotics on the human gut microbiome and intestinal integrity. Journal of Clinical Medicine, 14(11).

Plaza-Diaz, J., Ruiz-Ojeda, F. J., Gil-Campos, M., & Gil, A. (2019). Mechanisms of action of probiotics. Advances in Nutrition, 10(Suppl. 1), S49–S66.

van Trijp, M. P. H., Rios-Morales, M., Logtenberg, M. J., Keshtkar, S., Afman, L. A., Witteman, B., et al. (2024). Detailed analysis of prebiotic fructo- and galacto-oligosaccharides in the human small intestine. Journal of Agricultural and Food Chemistry, 72(38), 21152–21165.

Azcarate-Peril, M. A., Ritter, A. J., Savaiano, D., Monteagudo-Mera, A., Anderson, C., Magness, S. T., et al. (2017). Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals. Proceedings of the National Academy of Sciences of the United States of America, 114(3), E367–E375.

Gkolfakis, P., Tziatzios, G., Leite, G., Papanikolaou, I. S., Xirouchakis, E., Panayiotides, I. G., et al. (2023). Prevalence of small intestinal bacterial overgrowth syndrome in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: A cross-sectional study. Microorganisms, 11(3).

Berg, G., Rybakova, D., Fischer, D., Cernava, T., Vergès, M. C., Charles, T., et al. (2020). Microbiome definition re-visited: Old concepts and new challenges. Microbiome, 8(1), 103.

Martyniak, A., Wójcicka, M., Rogatko, I., Piskorz, T., & Tomasik, P. J. (2025). A comprehensive review of the usefulness of prebiotics, probiotics, and postbiotics in the diagnosis and treatment of small intestine bacterial overgrowth. Microorganisms, 13(1).

Rau, S., Gregg, A., Yaceczko, S., & Limketkai, B. (2024). Prebiotics and probiotics for gastrointestinal disorders. Nutrients, 16(6).

Mustafa, F., Noor, R., Murtaza, A., Kanwal, W., Kanwal, F., Kaleem, T., et al. (2025). Small intestinal bacterial overgrowth (SIBO)—Prevention and therapeutic role of nutrition, prebiotics, probiotics, and prokinetics. Current Pharmaceutical Design, 31(42), 3354–3364.

Rosania, R., Giorgio, F., Principi, M., Amoruso, A., Monno, R., Di Leo, A., et al. (2013). Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: A comparative evaluation. Current Clinical Pharmacology, 8(2), 169–172.

Yasukawa, Z., Inoue, R., Ozeki, M., Okubo, T., Takagi, T., Honda, A., et al. (2019). Effect of repeated consumption of partially hydrolyzed guar gum on fecal characteristics and gut microbiota: A randomized, double-blind, placebo-controlled, and parallel-group clinical trial. Nutrients, 11(9).

Kwak, D. S., Jun, D. W., Seo, J. G., Chung, W. S., Park, S. E., Lee, K. N., et al. (2014). Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. European Journal of Gastroenterology & Hepatology, 26(12), 1353–1359.

Rao, S. S. C., & Bhagatwala, J. (2019). Small intestinal bacterial overgrowth: Clinical features and therapeutic management. Clinical and Translational Gastroenterology, 10(10), e00078.

Hao, Y., Xu, Y., Ban, Y., Li, J., Wu, B., Ouyang, Q., et al. (2022). Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy. Frontiers in Cellular and Infection Microbiology, 12, 983027.

Alcedo González, J., Estremera-Arévalo, F., Cobián Malaver, J., Santos Vicente, J., Alcalá-González, L. G., Naves, J., et al. (2025). Common questions and rationale answers about the intestinal bacterial overgrowth syndrome (SIBO). Gastroenterología y Hepatología, 48(2), 502216.

Georgiou, K., Belev, N. A., Koutouratsas, T., Katifelis, H., & Gazouli, M. (2022). Gut microbiome: Linking together obesity, bariatric surgery and associated clinical outcomes under a single focus. World Journal of Gastrointestinal Pathophysiology, 13(3), 59–72.

Wagner, N. R. F., Ramos, M. R. Z., de Oliveira Carlos, L., da Cruz, M. R. R., Taconeli, C. A., Filho, A. J. B., et al. (2021). Effects of probiotics supplementation on gastrointestinal symptoms and SIBO after Roux-en-Y gastric bypass: A prospective, randomized, double-blind, placebo-controlled trial. Obesity Surgery, 31(1), 143–150.

Wagner, N. R. F., Lopes, M. C. P., Fernandes, R., Taconelli, C. A., Nascimento, G. M., Pessini, J., et al. (2024). Effects of probiotic use on gastrointestinal symptoms in the late postoperative period of bariatric surgery: A cross-over, randomized, triple-blind, placebo-controlled study. Obesity Surgery, 34(4), 1306–1315.

Kumar, K., Saadi, M., Ramsey, F. V., Schey, R., & Parkman, H. P. (2018). Effect of Bifidobacterium infantis 35624 (Align) on the lactulose breath test for small intestinal bacterial overgrowth. Digestive Diseases and Sciences, 63(4), 989–995.

Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020). ACG clinical guideline: Small intestinal bacterial overgrowth. The American Journal of Gastroenterology, 115(2), 165–178.

Kaźmierczak-Siedlecka, K., Ruszkowski, J., Fic, M., Folwarski, M., & Makarewicz, W. (2020). Saccharomyces boulardii CNCM I-745: A non-bacterial microorganism used as probiotic agent in supporting treatment of selected diseases. Current Microbiology, 77(9), 1987–1996.

McFarland, L. V. (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology, 16(18), 2202–2222.

Maev, I. V., Andreev, D. N., Shaburov, R. I., Zaborovsky, A. V., Fomenko, A. K., Sokolov, P. S., et al. (2025). [Study on the efficacy of combination therapy with rifaximin and. Terapevticheskii Arkhiv, 97(8), 660–667.

Redondo-Cuevas, L., Belloch, L., Martín-Carbonell, V., Nicolás, A., Alexandra, I., Sanchis, L., et al. (2024). Do herbal supplements and probiotics complement antibiotics and diet in the management of SIBO? A randomized clinical trial. Nutrients, 16(7).

García-Collinot, G., Madrigal-Santillán, E. O., Martínez-Bencomo, M. A., Carranza-Muleiro, R. A., Jara, L. J., Vera-Lastra, O., et al. (2020). Effectiveness of Saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Digestive Diseases and Sciences, 65(4), 1134–1143.

Efremova, I., Maslennikov, R., Zharkova, M., Poluektova, E., Benuni, N., Kotusov, A., et al. (2024). Efficacy and safety of a probiotic containing. Journal of Clinical Medicine, 13(3).